Abstract: Photodynamic therapy using 5-aminolevulinic acid is a treatment method in which the fluorescent substance of protoporphyrin IX excessively accumulated specifically in cancer cells is excited by visible red or green light irradiation, and reactive oxygen is produced and injures cancer cells. Photodynamic therapy using 5-aminolevulinic acid less markedly influences the surrounding normal cells and tissue as a result of no accumulation of protoporphyrin IX, being a low-invasive, less harmful treatment localized to cancer. Furthermore, photodynamic therapy using 5-aminolevulinic acid is painless, requiring no anesthesia because localized lesions are treated at a lowenergy level, and repeatedly applicable, unlike radiotherapy, and so is expected to be a new low-invasive treatment based on a concept completely different from existing treatments. In fact, photodynamic therapy using 5-aminolevulinic acid for bladder cancer was clinically demonstrated mainly for treatment-resistant bladder carcinoma in situ, and favorable outcomes have been obtained. Photodynamic therapy using 5-aminolevulinic acid are photodynamic technologies based on the common biological characteristic of cancers, and are expected as novel therapeutic strategies for many types of cancer.
Introduction
NMIBC accounts for approximately 70% of cases of bladder cancer at the time of diagnosis, and approximately 2-5% of these lesions are CIS. 1 CIS is often associated with polypoid tumors, which are associated with a poorer prognosis. 2 These CIS lesions are difficult to visualize by conventional cystoscopy (non-visible lesions), and they play a major role in intravesical recurrence of cancer after tumors TURBT, which is the standard treatment for NMIBC. Intravesical injection of BCG is the first-choice treatment for CIS of the bladder, with high complete response rates of approximately 76% after the initial treatment. 3 However, there is a high incidence of local symptoms, such as bladder irritation. Furthermore, systemic symptoms, such as fever, and although rare, serious disseminated BCG infections can occur. Thus, BCG must be used with caution in elderly patients. 4, 5 In other words, better detection protocols of bladder CIS and high-precision minimally-invasive treatments are required to improve the diagnostic accuracy of NMIBC and to improve treatment outcomes, respectively.
Recent attention has focused on the use of photodynamic technology using 5-ALA as a photosensitizer to solve the clinical problem of bladder cancer after the introduction of 5-ALA mediated photodynamic diagnosis for TURBT. 6, 7 ALA-PDD is indeed useful to detect and identify CIS in the bladder during TURBT. Therefore, we have already carried out phase III trials of ALA-PDD in Japan twice, [8] [9] [10] and its diagnostic drug approval is in progress. At present, there are 2469 publications of ALA-PDT on various types of cancer from basic study to clinical applications, and 857 of them are reports from clinical studies and practices according to the PubMed database. Although the clinical study of ALA-PDT for bladder cancer is relatively new among those reports, it has already been reviewed by Agostinis et al. 11 and Yavari et al. 12 Therefore, the present article reviews the use of ALA-PDT for bladder cancer aiming to promote the clinical study of ALA-PDT for bladder cancer, establish a better protocol in conjunction with the development of better light sources and devices, and prove its efficacy for approval as a standard therapeutic protocol for NMIBC, especially bladder CIS.
ALA-PDT
5-ALA is a natural amino acid found in animals and plants that is a common precursor of hemoglobin and chlorophyll. Endogenous 5-ALA, synthesized from succinyl coenzyme A and glycine in mitochondria, and exogenously administered 5-ALA follows the same metabolic synthetic pathway. Namely, through various precursors in the cytoplasm, this leads to biosynthesis of PpIX, the last precursor of heme, in mitochondria. PpIX is then catalyzed by ferrochelatase, and binds with ferrous ion resulting in the production of heme.
Cancer cells mainly utilize the glycolysis pathway for production of adenosine triphosphate, but do not run the tricarboxylic acid cycle or electron transport chain in mitochondria even in normoxia, which is called the Warburg effect and is typical for hyperplasia. In these conditions, the ferrochelatase is inactive because of the lack of electron supply from the tricarboxylic acid cycle, which is essential for reduction of ferric ion to ferrous ion to complete the production of heme by ferrochelatase. In various types of cancer including bladder cancer, biological features common to cancer cells, such as abnormal activity of transporters including ABCG2 and porphyrin synthetic enzymes, can promote PpIX production and inhibit PpIX catabolism. These features result in excess accumulation of PpIX in cancer cells. In particular, PpIX is 9-16-fold higher in urothelium and is highly tumor selective. 13 Because PpIX has photoactivity, excitation at certain wavelengths of light, particularly visible blue light (375-445 nm), causes red fluorescence (600-740 nm) to be emitted. This is the underlying principle of ALA-PDD (Fig. 1) . 14, 15 This has been used clinically for diagnosis of brain cancer, 16 ,17 bladder cancer [8] [9] [10] and gastric cancer. 18, 19 By supplying exogenous 5-ALA, PpIX is specifically accumulated in excess in cancer cells. When accumulated PpIX molecules are excited by specific wavelengths of light, such as visible red light (600-740 nm) and green light (450-580 nm), at low power, they absorb light energy and go up to an excitation state, and then return to a ground state. During this transitional stage, reactive oxygen species, such as hydroxy radicals, singlet oxygen, hydrogen peroxide and superoxide, are generated by energy conversion. The reactive oxygen species generated by these photochemical reactions damages cancer cells and induces apoptosis, which leads to cell death. This is the principle of ALA-PDT (Fig. 1) . 14, 20 In cells that undergo apoptosis, cytoplasmic condensation, cytoplasmic fragmentation and nuclear fragmentation occur. Cells in this state, including their cellular contents, are rapidly phagocytized by phagocytes, such as macrophages and neutrophils. Therefore, the inflammation usually caused by leakage of cellular contents with necrosis is suppressed, and there is minimal damage to surrounding cells and tissues. In other words, ALA-PDT, which shows anticancer efficacy mainly by apoptosis, is a treatment with few adverse effects.
Furthermore, these anticancer effects occur with low-energy excitation, so there is no pain, no need for narcotics and, unlike radiotherapy, treatment can be repeated. This makes ALA-PDT a very minimally-invasive treatment. In addition, similar to ALA-PDD, treatment is limited to cancer by specifically targeting the excess accumulation of PpIX in cancer cells. 14 This has already been approved for clinical treatment of solar keratosis and skin cancer in the USA and Europe. 21 
Photodynamic therapy for bladder cancer
PDT has a long history dating back to the early 20th century, when tumors were treated clinically with acridine or eosin dyes and light sources like the sun. Hematoporphyrin derivatives as photosensitizers were later developed, leading to PDT for gastric cancer and lung cancer. 22, 23 In 1976, Kelly et al. reported using PDT with a hematoporphyrin derivative and mercury arc lamp for treatment of bladder cancer. 24 In Japan in 1983, Hisazumi et al. first reported using PDT with a hematoporphyrin derivative and argon dye laser for 46 tumors in nine patients with NMIBC. 25 The PDT with a hematoporphyrin derivative was later actively used, but a high incidence of adverse events was reported. Those are phototoxicity reactions, mainly photosensitization, caused by systemic administration of hematoporphyrin derivatives, and contracted bladder as a result of total bladder laser irradiation. These events halted the widespread use of this treatment.
5-ALA as a photosensitizer for PDD and PDT for malignant tumors was first reported in 1987. 26 As mentioned previously, 5-ALA is a natural amino acid found in animals and plants, has low toxicity, is highly cancer specific, and is rapidly metabolized and excreted by normal cells using active transporters, such as ABCG2. Thus, 5-ALA has attracted attention as a third-generation photosensitizer. In both in vitro and in vivo animal studies, ALA-PDT has shown highly specific anticancer effects in human urothelial cancer cells 21 and prostate cancer cells. 27 In 1996, Kriegmair et al. first reported the use of ALA-PDT for bladder cancer in clinical trials. 28 Several clinical studies primarily in Europe were then reported. [30] [31] [32] [33] [34] The basic device setting can be seen in the report of the clinical study in a phase I setting carried out at the Department of Urology, Hope Hospital, and Salford Royal Hospitals Trust, Salford, UK (Fig. 2) . 30 These clinical studies mainly targeted patients with treatment-resistant bladder cancer or CIS bladder. The excitation light wavelengths used for treatment included 514 nm (green light), 630-635 nm (red light) and 380-700 nm (white light) for treatment with a low-heat density of 15-100 J/cm 2 . This treatment resulted in early response rates of 60-100% within 3-4 months after treatment, and response rates of 30-50% even 1.5-3 years after treatment (Table 1) . [28] [29] [30] [31] [32] [33] In these six clinical reports on ALA-PDT described above, only lowgrade local adverse events were observed, such as mild and transient hypotension and nausea after oral administration, and bladder irritation symptoms or hematuria after intravesical administration. However, no serious systemic adverse event occurred, such as phototoxic reactions, mainly photosensitive disease and liver disorder. [28] [29] [30] [31] [32] [33] In addition, in a phase I trial reported in 2013, the 5-ALA derivative HAL was used in 17 patients enrolled at two medical institutions involved in the trial for postoperative adjuvant treatment after TURBT of treatment-resistant NMIBC. 34 HAL is a hexyl ester derivative of 5-ALA and lipid soluble. HAL was designed to improve intratumor PpIX accumulation as an intravesical agent. However, its application cannot be expanded to systemic administration, because a hexyl ester hydrochloride shows strong cytotoxicity. HAL was used with white light (380-700 nm) for PDT given three times every 1.5 months. Lesions were absent in nine patients (52.9%) at 6 months after treatment, in four patients (23.5%) at 9 months after treatment and in two patients (11.8%) at 21 months after treatment. Very good outcomes, including safety outcomes, were reported.
5-ALA-PDT is currently not approved for treatment of bladder cancer. However, the indications for 5-ALA-PDT might expand as a high-precision treatment with minimal invasiveness, and might become an alternative to or additional to intravesical BCG instillation, the current standard treatment for bladder CIS.
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Discussion
The ALA-PDT was originally approved for treatment of actinic keratosis by the FDA in 2000. Since then, its applications have been expanded to treatment of non-melanoma skin cancers in dermatology, such as therapy of basal cell carcinoma, because of its cosmetic benefit (see the review article written by Ericson et al. 35 ). There are many review articles of ALA-PDT for skin cancers; however, there are not many in other oncology areas. Only a couple of reviews on ALA-PDT were found in the urology field. Although we have already carried out two phase III trials of ALA-PDD, the development stage of ALA-PDT for bladder cancer is still early because of the relatively low efficiency of ALA-PDT with blue or red light irradiation through water in the bladder. Therefore, we have not yet determined the best conditions for ALA-PDT on superficial bladder cancer, particularly CIS, in the presence of saline with which the bladder is filled. The present review aimed to promote the basic and clinical studies, and enhance the development of more efficient ALA-PDT for treatment of tiny superficial bladder cancers, which could remain even after TURBT with ALA-PDD. We are currently investigating various wavelength light sources to improve the efficiency of ALA-PDT in the bladder, particularly with our interest in the use of green light because of its energy level and tissue penetration ability.
Conclusion
5-ALA-PDT represents photodynamic technology for therapy for cancers based on the biological characteristics common among cancers, which depend on glycolysis but not mitochondrial respiration, and thus accumulate photosensitive PpIX, a precursor of heme. 5-ALA-PDT can be used clinically to treat various types of cancer including bladder cancer. 5-ALA-PDT is not painful, requires no narcotics, can be repeated and is a highly-targeted therapy. In particular, ALA-PDT might be useful for treatment of patients suffering from CIS when BCG therapy is not suitable. It is hoped that this technology can be applied as a minimallyinvasive treatment for the increasing elderly population in Japan. 
